Pharmacotherapy for end-stage coronary artery disease

Sodha, Neel R.;Chu, Louis M.;Boodhwani, Munir;Sellke, Frank W.
(2010) Expert Opinion on Pharmacotherapy — Vol. 11, n° 2, p. 207-213 (2010)

Files

pdfdocument.pdf
  • Open Access
  • Adobe PDF
  • 37.83 KB
Download

Details

Authors
  • Sodha, Neel R.Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Surg, Boston, MA 02215 USA
    Author
  • Chu, Louis M.Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Surg, Boston, MA 02215 USA
    Author
  • Boodhwani, MunirUCLouvain
    Author
  • Sellke, Frank W.Brown University, Warren Alpert School of Medicine, Division of Cardiothoracic Surgery, MOC 500, 2 Dudley Street, Providence, RI 02905, USA Read More: http://informahealthcare.com/doi/abs/10.1517/14656560903439737
    Author
Abstract
Importance of the field: Coronary artery disease remains the leading cause of mortality in the industrialized world. Despite advances in surgical and catheterbased interventions, a select number of patients remain with no options for invasive therapy. The goal of this review is to discuss the current status of pharmacotherapeutic interventions to treat end-stage coronary artery disease. Areas covered in this review: Literature review on the topic of therapeutic angiogenesis from 1980 to 2009. What the reader will gain: Insight into current therapeutic strategies employed to manage end-stage coronary artery disease. Take home message: A promising approach focuses on augmenting the endogenous angiogenic response to chronic myocardial ischemia via the use of growth factors.
Affiliations

Citations

  • APA
  • Chicago
  • FWB

Sodha, N. R., Chu, L. M., Boodhwani, M., & Sellke, F. W. (2010). Pharmacotherapy for end-stage coronary artery disease. Expert Opinion on Pharmacotherapy, 11(2), 207-213. https://doi.org/10.1517/14656560903439737 (Original work published 2010)